CClinicalTrials.gg
CompletedNCT00475540VAMPUpdated Oct 12, 2022Results posted

Efficacy Study of Vaginal Mesh for Prolapse

An interventional study of synthetic monofilament polypropylene mesh in Pelvic Organ Prolapse, Uterine Prolapse and Vaginal Prolapse, sponsored by Medstar Health Research Institute. Completed at 1 site in United States. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2022-10-12.

Sponsored by Medstar Health Research Institute · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
21 Years and older
Sex
Female
01

Study summary

The primary aim of this double-blind, randomized clinical trial (RCT) is to test the hypothesis that the addition of a standardized technique of interpositional synthetic polypropylene mesh placement improves the one-year outcome of vaginal reconstructive surgery for pelvic organ prolapse compared to traditional vaginal reconstructive surgery without mesh.

Read the detailed description

Minimally invasive surgical procedures using mesh have rapidly developed in the field of pelvic floor reconstruction. Unfortunately, safety and efficacy data have lagged behind the technical advancements. No randomized controlled trials of different vaginal apical suspension procedures have been reported. The use of synthetic vaginal mesh has evolved due to the 20-30% recurrence rate for conventional pelvic reconstructive surgeries. This trial will examine synthetic monofilament polypropylene mesh use in vaginal reconstructive surgery for vaginal Stage II-IV prolapse.

02

Conditions studied

  • Pelvic Organ Prolapse
  • Uterine Prolapse
  • Vaginal Prolapse
  • Cystocele
  • Rectocele

Keywords

  • prolapse
  • uterus
  • pelvic organ
  • vaginal prolpase
03

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Woman > 21 yrs
  • Stage II-IV vaginal prolapse
  • Desires vaginal reconstructive surgery
  • Able to complete study questionnaires and assessments
  • Uterus \< 12 weeks size
  • Available for 12 months follow-up

Exclusion criteria

Exclusion Criteria:

  • Medical contraindications, e.g. current urinary tract, vaginal or pelvic infection, history of pelvic irradiation, history of lower urinary tract malignancy, chronic steroid use or a compromised immune system.
  • Current intermittent catheterization.
  • Pregnancy or desire for future fertility.
  • Presence of an adnexal mass.
  • Shortened vagina or other known Mullerian anomaly (e.g. uterine didelphys).
  • Other laparoscopic or abdominal/pelvic surgery in the past 3 months.
  • Known neurologic or medical condition affecting bladder function, e.g. Multiple Sclerosis, spinal cord injury.
  • Need for concomitant surgery requiring an abdominal incision.
  • \< 12 months post-partum.
  • Non-english speaking
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Active comparator
    Prolift mesh

    vaginal prolapse repair with mesh

    Device: synthetic monofilament polypropylene mesh

  • Active comparator
    Prolapse repair without mesh

    vaginal prolapse repair without mesh

    Device: synthetic monofilament polypropylene mesh

Interventions

  • Devicesynthetic monofilament polypropylene mesh

    Vaginal prolapse repair with mesh

    Also known as: Prolift

05

What researchers measure

Primary outcomes

  1. Number of Participants With Anatomic Cure at 3 Years

    3 different measures for Anatomic cure using POPQ measurements: 1. POP-Q at Stage I or less\* (POP-Q points Ba, Bp or C -1 or less); 2. no prolapse beyond the hymen (Ba, Bp or C 0 or less); 3. no prolapse beyond the hymen (Ba, Bp 0 or less) with adequate apical support above the midvagina (C to TVL/2 or less) No bulge symptoms using Pelvic Floor Distress Inventory, PFDI question 3; do you see or feel a bulge in the vaginal area with response of no. Patient Satisfaction using Patient Global Impression of Improvement with response of very much better or much better

    Time frame: 3 year

Secondary outcomes

  1. Bothersome Dyspareunia

    Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire question 5 response of usually or always and tracked resolution, persistence, de novo dyspareunia

    Time frame: 3 year

06

Results

Posted Oct 12, 2022

Participant flow

From January 3, 2007 to August 1, 2009, 238 women were identified as eligible and 65 randomized (32 to experimental group (mesh) and 33 to control group (non-mesh)). All patients completed 3 month followup. Study recruitment halted at median followup of 9.7 months due to pre-determined criteria of vaginal mesh exposure in 5/32 patients (15.6%) in the mesh arm.

3 Months
Participant flow — 3 Months
MilestoneProlift MeshProlapse Repair Without Mesh
Started3233
Completed3233
Not completed00
12 Months
Participant flow — 12 Months
MilestoneProlift MeshProlapse Repair Without Mesh
Started3233
Completed3233
Not completed00
36 Months
Participant flow — 36 Months
MilestoneProlift MeshProlapse Repair Without Mesh
Started3332
Completed2526
Not completed86
Withdrew: Lost to follow-up44
Withdrew: Death12
Withdrew: Censored due to reoperation30

Outcome measures

PrimaryNumber of Participants With Anatomic Cure at 3 Years

3 different measures for Anatomic cure using POPQ measurements: 1. POP-Q at Stage I or less\* (POP-Q points Ba, Bp or C -1 or less); 2. no prolapse beyond the hymen (Ba, Bp or C 0 or less); 3. no prolapse beyond the hymen (Ba, Bp 0 or less) with adequate apical support above the midvagina (C to TVL/2 or less) No bulge symptoms using Pelvic Floor Distress Inventory, PFDI question 3; do you see or feel a bulge in the vaginal area with response of no. Patient Satisfaction using Patient Global Impression of Improvement with response of very much better or much better

Time frame:
3 year
Reported as:
Count of participants · Participants
Number of Participants With Anatomic Cure at 3 Years
ParticipantsProlift MeshProlapse Repair Without Mesh
no reoperation/retreatment2021
composite stage less than/equal 1, no bulge symptoms, satisfaction very much better or much better88
composite no prolapse beyond hymen, no bulge symptoms, satisfaction very much better or much better1512
Statistical analysis
  • Prolift Mesh vs Prolapse Repair Without Mesh · t-test, 2 sided · p = <0.05t-tests, Wilcoxon signed rank, Wilcoxon rank-sum tests continuous variables; X2 for categorical variables. Combined cure outcomes Fisher's exact test
SecondaryBothersome Dyspareunia

Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire question 5 response of usually or always and tracked resolution, persistence, de novo dyspareunia

Time frame:
3 year
Reported as:
Count of participants · Participants
Bothersome Dyspareunia
ParticipantsProlift MeshProlapse Repair Without Mesh
Persistent dyspareunia55
resolution dyspareunia21
de novo dyspareunia21

Adverse events

Collected over 3 months, 1 year, 3 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prolift Mesh1/32 (3.1%)5/32 (15.6%)0/32 (0%)
Prolapse Repair Without Mesh2/33 (6.1%)0/33 (0%)5/33 (15.2%)
Most frequent serious events
Most frequent serious events
EventProlift MeshProlapse Repair Without Mesh
Surgery/reoperation for mesh exposureSurgical and medical procedures5/320/33
Most frequent other events
Most frequent other events
EventProlift MeshProlapse Repair Without Mesh
suture exposureSurgical and medical procedures0/325/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)Prolift MeshProlapse Repair Without MeshTotal
Mean62.6 ± 10.663.1 ± 962.8 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Prolift MeshProlapse Repair Without MeshTotal
Female252651
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Prolift MeshProlapse Repair Without MeshTotal
White161733
African American6713
Hispanic224
Asian101
Postmenopausal
Postmenopausal(Participants)Prolift MeshProlapse Repair Without MeshTotal
Count of participants232447
Parity
Parity(number deliveries)Prolift MeshProlapse Repair Without MeshTotal
Median2 (2 to 3)2 (2 to 3)2 (2 to 3)
BMI
BMI(kg/m^2)Prolift MeshProlapse Repair Without MeshTotal
Mean27.6 ± 5.528.2 ± 6.427.9 ± 6.0
POP-Q stage
POP-Q stage(Participants)Prolift MeshProlapse Repair Without MeshTotal
stage 27411
stage 3161834
stage 4246
married
married(Participants)Prolift MeshProlapse Repair Without MeshTotal
Count of participants161935

5 further baseline measures are reported on the registry.

07

Study locations

1 site
  • Washington Hospital Center
    Washington, District of Columbia 20010, United States
08

References and documents

Publications

  • Gutman RE, Nosti PA, Sokol AI, Sokol ER, Peterson JL, Wang H, Iglesia CB. Three-year outcomes of vaginal mesh for prolapse: a randomized controlled trial. Obstet Gynecol. 2013 Oct;122(4):770-777. doi: 10.1097/AOG.0b013e3182a49dac. PubMed 24084533 ↗
  • Iglesia CB, Sokol AI, Sokol ER, Kudish BI, Gutman RE, Peterson JL, Shott S. Vaginal mesh for prolapse: a randomized controlled trial. Obstet Gynecol. 2010 Aug;116(2 Pt 1):293-303. doi: 10.1097/AOG.0b013e3181e7d7f8. PubMed 20664388 ↗
09

Registry details

Key details

Study ID
NCT00475540
Lead sponsor
Medstar Health Research Institute
Responsible party
Sponsor
First posted
May 21, 2007
Start date
Jan 2007
Primary completion
Aug 2012
Completion
Aug 2013
Results posted
Oct 12, 2022
Last update
Oct 12, 2022

Study contacts

Cheryl Iglesia, MD
principal investigator · Medstar Health Research Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion